EMA favors Genmab’s oncology star
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5717140.ece/ALTERNATES/schema-16_9/Genmab_logo_silver_on_green.jpg)
Danish biotech company Genmab moved one step closer to a European approval of its cancer treatment daratumumab on Friday, as the the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting conditional marketing authorization to the drug in the EU to treat relapsed and refractory multiple myeloma.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”It could be the beginning of a new era for daratumumab”
For abonnenter
Double success for Genmab
For abonnenter